Citations (56)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Catherine Datto, Richard Hellmund & Mohd Kashif Siddiqui. (2013) Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses. Open Access Rheumatology: Research and Reviews 5, pages 1-19.
Read now
Read now
Marc C. Hochberg, John G. Fort, Ola Svensson, Clara Hwang & Mark Sostek. (2011) Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials. Current Medical Research and Opinion 27:6, pages 1243-1253.
Read now
Read now
Alaa Rostom, Katherine Muir, Catherine Dube, Angel Lanas, Emilie Jolicoeur & Peter Tugwell. (2009) Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug, Healthcare and Patient Safety 1, pages 47-71.
Read now
Read now
Bernard Bannwarth & Francis Bérenbaum. (2007) Lumiracoxib in the management of osteoarthritis and acute pain. Expert Opinion on Pharmacotherapy 8:10, pages 1551-1564.
Read now
Read now
Raban V Jeger, Jeffrey D Greenberg, Krishnan Ramanathan & Michael E Farkouh. (2005) Lumiracoxib, a highly selective COX-2 inhibitor. Expert Review of Clinical Immunology 1:1, pages 37-45.
Read now
Read now
Articles from other publishers (51)
Christopher Vannabouathong, Meng Zhu, Yaping Chang & Mohit Bhandari. (2021) Can Medical Cannabis Therapies be Cost-Effective in the Non-Surgical Management of Chronic Knee Pain?. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 14, pages 117954412110024.
Crossref
Crossref
Eeva-Eerika Helminen, Jari PA Arokoski, Tuomas A Selander & Sanna H Sinikallio. (2020) Multiple psychological factors predict pain and disability among community-dwelling knee osteoarthritis patients: a five-year prospective study. Clinical Rehabilitation 34:3, pages 404-415.
Crossref
Crossref
Moe H. Kyaw, Alaa Rostom, Katherine Muir, Catherine Dubé, Emilie Jolicoeur, Michel Boucher, Peter Tugwell, George Wells & Francis K.L. Chan. 2019. Evidence-based Gastroenterology and Hepatology 4e. Evidence-based Gastroenterology and Hepatology 4e
86
109
.
Elizabeth Curtis, Nicholas Fuggle, Sarah Shaw, Laura Spooner, Georgia Ntani, Camille Parsons, Nadia Corp, Germain Honvo, Janis Baird, Stefania Maggi, Elaine Dennison, Olivier Bruyère, Jean-Yves Reginster & Cyrus Cooper. (2019) Safety of Cyclooxygenase-2 Inhibitors in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs & Aging 36:S1, pages 25-44.
Crossref
Crossref
Kristin Salottolo, Brian Cole & David Bar-Or. (2018) Intra-articular injection of the anti-inflammatory compound LMWF-5A in adults with severe osteoarthritis: a double-blind prospective randomized controlled multi-center safety and efficacy trial. Patient Safety in Surgery 12:1.
Crossref
Crossref
David S. Jevsevar, Peter B. Shores, Kyle Mullen, Danielle M. Schulte, Gregory A. Brown & Deborah S. Cummins. (2018) Mixed Treatment Comparisons for Nonsurgical Treatment of Knee Osteoarthritis: A Network Meta-analysis. Journal of the American Academy of Orthopaedic Surgeons 26:9, pages 325-336.
Crossref
Crossref
Brian Cole, Brian McGrath, Kristin Salottolo & David Bar-Or. (2018) LMWF-5A for the Treatment of Severe Osteoarthritis of the Knee: Integrated Analysis of Safety and Efficacy. Orthopedics 41:1.
Crossref
Crossref
Livia Puljak, Ana Marin, Davorka Vrdoljak, Filipa Markotic, Ana Utrobicic & Peter Tugwell. (2017) Celecoxib for osteoarthritis. Cochrane Database of Systematic Reviews 2017:7.
Crossref
Crossref
Eeva-Eerika Helminen, Sanna H Sinikallio, Anna L Valjakka, Rauni H Väisänen-Rouvali & Jari PA Arokoski. (2016) Determinants of pain and functioning in knee osteoarthritis: a one-year prospective study. Clinical Rehabilitation 30:9, pages 890-900.
Crossref
Crossref
Chul-Won Ha, Yong-Beom Park, Hee-Soo Kyung, Chung-Soo Han, Ki-Cheor Bae, Hong-Chul Lim, Sang-Eun Park, Myung Chul Lee, Ye-Yeon Won, Dong-Chul Lee, Sung-Do Cho, Chang-Wan Kim, Jin-Goo Kim, Joon-Soon Kang, Ju-Hong Lee, Eui-Sung Choi, Jong-Keun Seon, Woo-Suk Lee & Seong-Il Bin. (2016) Gastrointestinal safety and efficacy of long-term GCSB-5 use in patients with osteoarthritis: A 24-week, multicenter study. Journal of Ethnopharmacology 189, pages 310-318.
Crossref
Crossref
S.R. Smith, B.R. Deshpande, J.E. Collins, J.N. Katz & E. Losina. (2016) Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. Osteoarthritis and Cartilage 24:6, pages 962-972.
Crossref
Crossref
Chao Xu, Ke Gu, Yalikun Yasen & Yanjie Hou. (2016) Efficacy and Safety of Celecoxib Therapy in Osteoarthritis. Medicine 95:20, pages e3585.
Crossref
Crossref
Raveendhara R. BannuruTimothy E. McAlindonMatthew C. SullivanJohn B. WongDavid M. KentChristopher H. Schmid. (2015) Effectiveness and Implications of Alternative Placebo Treatments. Annals of Internal Medicine 163:5, pages 365-372.
Crossref
Crossref
Chao Zeng, Jie Wei, Hui Li, Tuo Yang, Shu-guang Gao, Yu-sheng Li, Yi-lin Xiong, Wen-feng Xiao, Wei Luo, Tu-bao Yang & Guang-hua Lei. (2015) Comparison between 200 mg QD and 100 mg BID oral celecoxib in the treatment of knee or hip osteoarthritis. Scientific Reports 5:1.
Crossref
Crossref
Julie Myers, Ronald C Wielage, Baoguang Han, Karen Price, James Gahn, Marie-Ange Paget & Michael Happich. (2014) The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: a systematic literature review and meta-analysis. BMC Musculoskeletal Disorders 15:1.
Crossref
Crossref
Miguel Elizondo-Cano, Fernando Carlos-Rivera, Jocelyn Ramírez-Gámez & Héctor Dueñas. (2014) Evaluación económica del uso de duloxetina en el tratamiento del dolor crónico causado por osteoartritis de rodilla en el sistema privado de salud en México. PharmacoEconomics Spanish Research Articles 11:3, pages 61-72.
Crossref
Crossref
Brian Birmingham & Asokumar Buvanendran. 2014. Practical Management of Pain. Practical Management of Pain
553
568.e5
.
Ronald C. Wielage, Julie A. Myers, Robert W. Klein & Michael Happich. (2013) Cost-Effectiveness Analyses of Osteoarthritis Oral Therapies: a Systematic Review. Applied Health Economics and Health Policy 11:6, pages 593-618.
Crossref
Crossref
Yong-Geun Park, Chul-Won Ha, Chang-Dong Han, Seong-Il Bin, Hee-Chun Kim, Young-Bok Jung & Hong-Chul Lim. (2013) A prospective, randomized, double-blind, multicenter comparative study on the safety and efficacy of Celecoxib and GCSB-5, dried extracts of six herbs, for the treatment of osteoarthritis of knee joint. Journal of Ethnopharmacology 149:3, pages 816-824.
Crossref
Crossref
Isla S. Mackenzie, Li Wei & Thomas M. MacDonald. (2012) Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritis. European Journal of Clinical Pharmacology 69:2, pages 133-141.
Crossref
Crossref
Mn Essex, M O'Connell & P Bhadra Brown. (2012) Response to Nonsteroidal Anti-inflammatory Drugs in African Americans with Osteoarthritis of the Knee. Journal of International Medical Research 40:6, pages 2251-2266.
Crossref
Crossref
MARC C. HOCHBERG, MADELAINE WOHLREICH, PAULA GAYNOR, SYLVIA HANNA & RICK RISSER. (2012) Clinically Relevant Outcomes Based on Analysis of Pooled Data from 2 Trials of Duloxetine in Patients with Knee Osteoarthritis. The Journal of Rheumatology 39:2, pages 352-358.
Crossref
Crossref
Paul L. McCormack. (2011) Celecoxib. Drugs 71:18, pages 2457-2489.
Crossref
Crossref
Thomas J. Schnitzer, I. Dan Dattani, Bruno Seriolo, Hartmut Schneider, Alan Moore, Lillian Tseng, Peter Sallstig, Rosemary Rebuli & Thomas Maxwell. (2011) A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis. Clinical Rheumatology 30:11, pages 1433-1446.
Crossref
Crossref
Alaa Rostom, Katherine Muir, Catherine Dubé, Emilie Jolicoeur, Michel Boucher, Peter Tugwell & George Wells. 2010. Evidence‐Based Gastroenterology and Hepatology. Evidence‐Based Gastroenterology and Hepatology
139
164
.
S. Trijau, J. Avouac, C. Escalas, L. Gossec & M. Dougados. (2010) Influence of flare design on symptomatic efficacy of non-steroidal anti-inflammatory drugs in osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis and Cartilage 18:8, pages 1012-1018.
Crossref
Crossref
T. M. MacDonald, D. Richard, K. Lheritier & G. Krammer. (2010) The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents. International Journal of Clinical Practice 64:6, pages 746-755.
Crossref
Crossref
Clara C Chan, Christopher M Reid, Tai-Juan Aw, Danny Liew, Steven Joseph Haas & Henry Krum. (2009) Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. Journal of Hypertension 27:12, pages 2332-2341.
Crossref
Crossref
C. O. Bingham, S. S. Smugar, H. Wang & A. M. Tershakovec. (2009) Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo. Rheumatology 48:9, pages 1122-1127.
Crossref
Crossref
Shahram SADREDDINI, Hamid NOSHAD, Mahshid MOLAEEFARD, Ramona MOLOUDI, Mohamad-Reza ARDALAN & Morteza GHOJAZADEH. (2009) A double blind, randomized, placebo controlled study to evaluate the efficacy of erythromycin in patients with knee effusion due to osteoarthritis. International Journal of Rheumatic Diseases 12:1, pages 44-51.
Crossref
Crossref
Iris Contreras-Hernández, Joaquín F Mould-Quevedo, Rubén Torres-González, María Victoria Goycochea-Robles, Reyna Lizette Pacheco-Domínguez, Sergio Sánchez-García, Juan Manuel Mejía-Aranguré & Juan Garduño-Espinosa. (2008) Cost-effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs. cyclooxygenase-2 selective inhibitors. Cost Effectiveness and Resource Allocation 6:1.
Crossref
Crossref
Roy Fleischmann, Hyman Tannenbaum, Neha P Patel, Marianne Notter, Peter Sallstig & Jean-Yves Reginster. (2008) Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis. BMC Musculoskeletal Disorders 9:1.
Crossref
Crossref
Loren Laine, William B. White, Alaa Rostom & Marc Hochberg. (2008) COX-2 Selective Inhibitors in the Treatment of Osteoarthritis. Seminars in Arthritis and Rheumatism 38:3, pages 165-187.
Crossref
Crossref
C. Kyle, J. Zachariah, H. Kinch, G. Ellis, C. Andrews & F. Adekunle. (2008) A randomised, double-blind study comparing lumiracoxib with naproxen for acute musculoskeletal pain. International Journal of Clinical Practice 62:11, pages 1684-1692.
Crossref
Crossref
C.O. BinghamIIIIII, S.R. Bird, S.S. Smugar, X. Xu & A.M. Tershakovec. (2008) Responder analysis and correlation of outcome measures: pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis. Osteoarthritis and Cartilage 16:11, pages 1289-1293.
Crossref
Crossref
Michael E. FarkouhFreek W. A. VerheugtSean RulandHoward KirshnerRaban JegerXavier GittonGerhard KrammerKirstin StrickerPeter SallstigBernhard MelleinPatrice MatchabaJames H. Chesebro. (2008) A Comparison of the Blood Pressure Changes of Lumiracoxib With Those of Ibuprofen and Naproxen. The Journal of Clinical Hypertension 10:8, pages 592-602.
Crossref
Crossref
Thomas M MacDonald, Jean-Yves Reginster, Thomas W Littlejohn, Dominik Richard, Karine Lheritier, Gerhard Krammer & Rosemary Rebuli. (2008) Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. Journal of Hypertension 26:8, pages 1695-1702.
Crossref
Crossref
Roger Jones, Greg Rubin, Francis Berenbaum & James Scheiman. (2008) Gastrointestinal and Cardiovascular Risks of Nonsteroidal Anti-inflammatory Drugs. The American Journal of Medicine 121:6, pages 464-474.
Crossref
Crossref
Christopher J. Hawkey, Christian Ell, Bernd Simon, Jörg Albert, Martin Keuchel, Mark McAlindon, Paul Fortun, Stefan Schumann, Wolfgang Bolten, Anthony Shonde, Jean–Louis Hugot, Vincent Yu, Udayasankar Arulmani, Gerhard Krammer, Rosemary Rebuli & Ervin Toth. (2008) Less Small-Bowel Injury With Lumiracoxib Compared With Naproxen Plus Omeprazole. Clinical Gastroenterology and Hepatology 6:5, pages 536-544.
Crossref
Crossref
Shaojun Shi & Ulrich Klotz. (2007) Clinical use and pharmacological properties of selective COX-2 inhibitors. European Journal of Clinical Pharmacology 64:3, pages 233-252.
Crossref
Crossref
Paul Emery, Tamas Koncz, Sharon Pan & Simon Lowry. (2008) Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multicenter, randomized, double-blind, parallel-group, double-dummy, noninferiority study. Clinical Therapeutics 30:1, pages 70-83.
Crossref
Crossref
Asokumar Buvanendran & Scott S. Reuben. 2008. Raj's Practical Management of Pain. Raj's Practical Management of Pain
671
692
.
Seong-II BIN, Shing-Sheng WU, Xiaofeng ZENG, Alan MOORE & Nicole FRANK. (2007) Efficacy of lumiracoxib in relieving pain associated with knee osteoarthritis: a 6-week, randomized, double-blind, parallel-group study. APLAR Journal of Rheumatology 10:3, pages 190-197.
Crossref
Crossref
Alaa Rostom, Katherine Muir, Catherine Dubé, Emilie Jolicoeur, Michel Boucher, Janet Joyce, Peter Tugwell & George W. Wells. (2007) Gastrointestinal Safety of Cyclooxygenase-2 Inhibitors: A Cochrane Collaboration Systematic Review. Clinical Gastroenterology and Hepatology 5:7, pages 818-828.e5.
Crossref
Crossref
Jan Magnus Bjordal, Atle Klovning, Anne Elisabeth Ljunggren & Lars Slørdal. (2007) Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials. European Journal of Pain 11:2, pages 125-138.
Crossref
Crossref
Asokumar Buvanendran, Scott S. Reuben & Jeffrey S. Kroin. (2007) Recent advances in nonopioid analgesics for acute pain management. Techniques in Regional Anesthesia and Pain Management 11:1, pages 19-26.
Crossref
Crossref
L-C. Chen & D. M. Ashcroft. (2006) Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials. Journal of Clinical Pharmacy and Therapeutics 31:6, pages 565-576.
Crossref
Crossref
. (2006) Glucosamine and Chondroitin Sulfate for Knee Osteoarthritis. New England Journal of Medicine 354:20, pages 2184-2185.
Crossref
Crossref
Daniel O. Clegg, Domenic J. Reda, Crystal L. Harris, Marguerite A. Klein, James R. O'Dell, Michele M. Hooper, John D. Bradley, Clifton O. BinghamIIIIII, Michael H. Weisman, Christopher G. Jackson, Nancy E. Lane, John J. Cush, Larry W. Moreland, H. Ralph SchumacherJr.Jr., Chester V. Oddis, Frederick Wolfe, Jerry A. Molitor, David E. Yocum, Thomas J. Schnitzer, Daniel E. Furst, Allen D. Sawitzke, Helen Shi, Kenneth D. Brandt, Roland W. Moskowitz & H. James Williams. (2006) Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis. New England Journal of Medicine 354:8, pages 795-808.
Crossref
Crossref
Shridhar Hegde & Michelle Schmidt. 2006. Annual Reports in Medicinal Chemistry Volume 41. Annual Reports in Medicinal Chemistry Volume 41
439
477
.
Patrice Matchaba, Xavier Gitton, Gerhard Krammer, Elena Ehrsam, Victor Schorr Sloan, Melvin Olson, Bernhard Mellein, Godehard Hoexter, John Orloff & Jean-Jacques Garaud. (2005) Cardiovascular safety of lumiracoxib: A meta-analysis of all randomized controlled trials ≥1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis. Clinical Therapeutics 27:8, pages 1196-1214.
Crossref
Crossref